Peak Bggrflipped into Biotech Investing7 hours agoJohnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?The Motley Fool - Brendan CoffeyJNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration …
Peak Bggrflipped into Biotech Investing9 hours agoReplimune announces Tudriqev now available in U.S. for advanced melanomatipranks.com - TheFlyReplimune (REPL) Group announced that Tudriqev is now commercially available in the United States. Tudriqev is indicated in combination with …
Peak Bggrflipped into Biotech Investing16 hours ago5 common infections now linked to millions of cancer casesrollingout.com - Shekari PhilemonCancer has long been associated with genetics, lifestyle choices and environmental exposure. But a growing body of research is pointing to a cause …
Peak Bggrflipped into Biotech Investing14 hours agoModerna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water247wallst.com - David MoadelBuyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) …
Peak Bggrflipped into Biotech Investing17 hours agoEvommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressAOLPALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Oct 1, 2026-- Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a …
Peak Bggrflipped into Biotech Investing13 hours agoA Drug Extended Lifespan in 3 Very Different Species by More Than 25% Longer in a New Longevity StudyZME Science - Tibi PuiuDirectly activating a cellular energy sensor extended lifespan across three very different organisms. When energy runs short, cells redo their budget …
